Impax Laboratories Inc

Impax Laboratories — Q4 2015 Earnings Presentation

32 slides from Impax Laboratories's earnings presentation, Feb 22, 2016

  1. Slide 1: Fourth Quarter 2015 Earnings Conference Call

    mpax ourth Quarter 2015 _ arnings Conference ail ruary 22, 2016

  2. Slide 2: Impax Cautionary Statement Regarding Forward Looking Statements

    Impax Cautionary Statement Regarding Forward Looking Statements “Safe Harbor" statement under the Private Securties Litigation Reform Act of 1996: To the extent any statements made in this presentation contain information that is not historical; these statements are forward-looking in nature and exp

  3. Slide 3: Agenda

    Agenda

  4. Slide 4: Highlights & Update

    Highlights & Update Fred Wilkinson President & Chief Executive Officer

  5. Slide 5: 4Q 2015 Financial Highlights

    4Q 2015 Financial Highlights Poti | ans | 4a | change | Total Revenues $282 $131 115% $860 $596 44% Adjusted Diluted EPS $0.62 $0.16 288% $1.45 $1.32 10% | + 4Q15 compared to 4Q14 » Higher generic product volumes led by diclofenac sodium gel — Sole supplier of diclofenac due to competitor temporaril

  6. Slide 6: 2015 Highlights - Four Strategic Pillars

    2015 Highlights - Four Strategic Pillars im_ Focus on Quality and Operations + Resolved Warning Letter in Hayward + Passed EMA (MHRA) inspection and GMP license granted in Taiwan + Successfully transferred and closed central packaging operation in Pennsyivania + Transferred product distribution to U

  7. Slide 7: Maximizing Generic Platform

    Maximizing Generic Platform Targeting 12 to 14 Potential Launches in 2016 Potential Launches Targeted in 2016 Current U.S. Brand/Generic market sales of $4.7B More than 50% of Current ANDA Pipeline has Target Action Dates ‘Source of sales data: MS Dec. 2015; Pipeline data as ofFeb. 16, 2018 Impa3)

  8. Slide 8: Maximizing Specialty Pharma Platform

    Maximizing Specialty Pharma Platform * Growth tracking to long range plan + Strong product interest results in enhanced physician office access + Driving awareness and adoption >86% of commercial and Medicare Part D Rx’s approved by payers + 2% share of carbidopa/ levodopa segment ieee Monthly TRx a

  9. Slide 9: Maximizing Specialty Pharma Platform: Launching Second Quarter 2016

    Maximizing Specialty Pharma Platform Launching Second Quarter 2016 + Approval of EMVERM™ (mebendazole) enhances anthelmintic franchise in IS BACK addition to Albenza WITH TS 95% CURE RATE® + Pinworm is a highly contagious parasite pee earereer hire that infects approximately 40 million MEBENOAZOLE A

  10. Slide 10: Expanding and Internalizing Sales Force in 2016

    Maximizing Specialty Pharma Platform Expanding and Internalizing Sales Force in 2016 # of CNS Sales Reps Approximately 120 - . * Builds scale to support organic growth 7 + Provides increased geographic reach 66 and frequency + Strong interest in Rytary results in enhanced physician office access + R

  11. Slide 11: Optimizing Generic R&D

    Optimizing Generic R&D Multiple Product Opportunities to Drive Future Growth Abbreviated New Drug Applications (ANDAs) 25 Products Pending at FDA 18 Products Under Development Current U.S. Brand/Generic Market - $8B Current U.S. Brand/Generic Market - $10B 24% Potential/Confirmed FTF or FTM 50% Pote

  12. Slide 12: Accelerating Business Development

    Accelerating Business Development Targeting Strategic Value Creating Opportunities Financial Resources and Flexibility to Support Growth + Strong balance sheet as of December 31, 2015 » Cash position of $340 million » No senior secured debt outstanding » Leverage less than 1.2x net debt to 2015 adju

  13. Slide 13: Growing and Investing in Our Future in 2016

    Growing and Investing in Our Future in 2016 Double digit revenue growth Double digit EPS growth Investing to support current and long-term growth » Increasing investment in R&D » Increasing investment in Specialty Pharma sales force Continuing to invest in global quality and compliance systems, whil

  14. Slide 14: Financial Review

    Financial Review Bryan Reasons Senior Vice President & Chief Financial Officer

  15. Slide 15: 4Q 2015 Financial Summary

    4Q 2015 Financial Summary | 40.2014 | Change | Total Revenues $282.1 $221.1 27.6% $131.2 115.0% Adjusted Gross Margin 49.0% 50.3% (1.3)ppts 51.4% (2.4)ppts Adjusted R&D Expense $19.4 $17.9 8.4% $15.4 26.0% Adjusted SG&A Expense $53.0 $42.5 24.7% $35.7 48.5% Adjusted EBITDA $78.4 $65.8 19.1% $27.4 18

  16. Slide 16: 4Q 2015 Generic Division Performance

    4Q 2015 Generic Division Performance | 40.2014 | Change | Total Revenues $226.8 $180.7 25.5% $117.9 92.4% Adjusted Gross Margin 40.5% 42.8% (2.3)ppts 49.8% (9.3)ppts | Adjusted Operating Income $64.8 $58.3. 11.1% $47.0 37.9% | 4Q 2015 comparedto 4Q 2014 + Significant revenue growth primarily driven

  17. Slide 17: 4Q 2015 Specialty Pharma Division Performance

    ‘mo Tow 4Q 2015 Specialty Pharma Division Performance Total Revenues $55.2 $40.4 36.6% $13.3 315.0% Adjusted Gross Margin 83.6% 83.7% (0.1)ppts 65.5% 18.1ppts Adjusted Operating Income $26.7 $17.5 52.6% ($10.1) - 4Q 2015 comparedto 4Q 2014 + Significant revenue growth driven by the launch of Rytary,

  18. Slide 18: 2016 Financial Guidance

    2016 Financial Guidance The Company’s full year 2016 estimates are based on management's current expectations, including with respect to prescription trends, pricing levels, inventory levels, and the anticipated timing of future product launches and events. The following statements are forward-looki

  19. Slide 19: 2016 Revenue Guidance

    2016 Revenue Guidance Total Company Revenue S$ millions + Targeting 12 to 14 generic product launches » 6 products approved/re-launched — Includes authorized generic At Least Oxycontin® ~15% Growth* > 6to8 potential approvals among 25 $860 pending ANDAs — More than 50% of pending ANDAs have Target A

  20. Slide 20: 2016 Key Product Assumptions

    2016 Key Product Assumptions Full Year 2016 Assumptions Compared to Full Year 2015 * Generic diclofenac 3% gel (Solaraze®) » Generic competition expected first half 2016; Brand reestablishes itself second half 2016 * Generic Adderall XR® > Transition existing authorized generic supply to Impax ANDA

  21. Slide 21: 2016 Gross Margin Guidance

    2016 Gross Margin Guidance Adjusted Gross Margin + Includes: > Targeting 12to 14 generic product launches. > Significant revenue contribution from generic partnered products 62% — A imatet > Impactof growth from brand products Pprommarely |. Excludes: 49% 50%* . . > Higher-value pending ANDAs such a

  22. Slide 22: 2016 R&D Expense Guidance

    2016 R&D Expense Guidance Adjusted R&D and Patent Litigation Expense Approximately * 9% 10% + R&D expense of approximately $100 to $105 million + Investing in Generic R&D » 25 pending ANDAs and 18 projects under development » Hayward R&D team re-focusing on product developmentversus remediation » In

  23. Slide 23: 2016 SG&A Expense Guidance

    2016 SG&A Expense Guidance Adjusted SG&A Expense + SG&A expense of approximately $200 to $210 million + Investing to support organic Specialty 22% Approximately Pharma growth 21% 20% 20% - 21%* » From77 reps to approximately 120 18% » Primary benefitis increased frequency on target audience » Three

  24. Slide 24: 2016 Financial Guidance Summary

    2016 Financial Guidance Summary Met iscal 2016 Guidance Revenue Increase at least 15% over full year 2015 total revenue Adjusted gross margin Approximately 50% Approximately $100 to $105 million (Approximately 10% of total revenue) Approximately $200 to $210 million R&D and patent litigation expense

  25. Slide 25: Q&A

  26. Slide 26: Appendix

    Appendix

  27. Slide 27: Pending ANDA Pipeline

    Pending ANDA Pipeline 25 Pending ANDAsat FDA | Disclosed Pending ANDAs Include*: ‘Sevelamer Carbonate IR tablet (Renvela®) Colesevelam IR tablet (Welchol®) Fenofibric Acid DR capsule (Trlipix®) Ezetimibe Simvastatin IR tablet (Vytorin®) - TA Oxycodone ER tablet (new formulation) (Oxycontin®) Dutaste

  28. Slide 28: GAAP to Adjusted Net Income Reconciliation

    GAAP to Adjusted Net Income Reconciliation ‘The following table reconciles reported net income (loss) to adjusted net income. (Unaudited, amounts in thousands, except per share and per share data) Three months ended Year Ended Dec.31, Sept. 31, Dec. 31, December 31, 2015 2015 2014 2015 2014 Net inco

  29. Slide 29: GAAP to Adjusted Results Reconciliation

    GAAP to Adjusted Results Reconciliation The following table reconciles total Company reported cost of revenues, research and development expenses, and selling, general and administrative expenses to adjusted cost of revenues, adjusted gross profit, adjusted gross margin, adjusted research and develo

  30. Slide 30: GAAP to Adjusted EBITDA Reconciliation

    GAAP to Adjusted EBITDA Reconciliation The following table reconciles reported net income (loss) to adjusted EBITDA. (Unaudited, amounts in thousands) Three months ended Dec.31, Sept. 31, Dec. 31, 2015, 2015 2014 Net income S 11427 S$ 35755 $120 Adjusted to add (deduct) Interest income (i) (247) (35

  31. Slide 31: Generic Division GAAP to Adjusted Reconciliation

    Generic Division GAAP to Adjusted Reconciliation The following tables reconcile the Impax Generics Division reported cost of revenues to adjusted cost of revenues, adjusted gross profit, adjusted gross margin and adjusted operating income (Unaudited, amounts in thousands) Reported to Adjusted Result

  32. Slide 32: Specialty Pharma Division GAAP to Adjusted Reconciliation

    Specialty Pharma Division GAAP to Adjusted Reconciliation The following tables reconcile the Impax Specialty Pharma Divisions reported cost of revenues to adjusted cost of revenues, adjusted gross profit, adjusted gross margin and adjusted operating income (Unaudited, amounts in thousands) Three Mon

Impax Laboratories — Q4 2015 Earnings Presentation on 6ix